Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: Results of a Phase I clinical trial

British Journal of Haematology

Volumn 143, Issue 2, 2008, Pages 191-200

  Pönisch, Wolfram ^a   Rozanski, Marta ^a   Goldschmidt, Hartmut ^b   Hoffmann, Franz Albert ^c   Boldt, Thomas ^d   Schwarzer, Andreas ^c   Ritter, Ute ^c   Rohrberg, Robert ^c   Schwalbe, Elke ^e   Uhlig, Jens ^c   Zehrfeld, Thomas ^f   Schirmer, Veronika ^g   Haas, Antje ^h   Kreibich, Ute ⁱ   Niederwieser, Dietger ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Hospital Friedrichstadt ^*

^d ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^e DESSAU MEDICAL CENTER   (Germany)

^f Hospital Johann Kentmann   (Germany)

^g Childrens Hospital   (Germany)

^h Ernst von Bergmann Hospital   (Germany)

ⁱ Heinrich Braun Krankenhaus   (Germany)

Author keywords

Advanced multiple myeloma; Bendamustine; Phase I study; Prednisolone; Thalidomide

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; BENDAMUSTINE; BORTEZOMIB; CORTICOSTEROID; PREDNISOLONE; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING;

EID: 52649146310     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07076.x     Document Type: Article

References (52)

1. Alexanian, R. Dimopoulos, M. (1994) The treatment of multiple myeloma. New England Journal of Medicine, 330, 484 489.
2. Anagnostopoulos, A., Weber, D., Rankin, K., Delasalle, K. Alexanian, R. (2003) Thalidomide and dexamethasone for resistant multiple myeloma. British Journal of Haematology, 121, 768 771.
3. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 91 97.
4. Balfour, J.A. Goa, K.L. (2001) Bendamustine. Drugs, 61, 631 638 discussion 639 640.
5. Blade, J. Esteve, J. (2000) Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncologica, 39, 843 847.
6. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115 1123.
7. Bremer, K. (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's- lymphomas. Journal of Cancer Research and Clinical Oncology, 128, 603 609.
8. Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210 216.
9. Dimopoulos, M.A., Panayiotidis, P., Grigoraki, V., Poziopoulos, C., Xilouri, I., Kiamouris, C., Tassidou, A., Gika, D., Stefanoudaki, K., Anagnostopoulos, N. Anagnostou, D. (2001) Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma. Blood, 98, 164A.
10. Dimopoulos, M.A., Hamilos, G., Zomas, A., Gika, D., Efstathiou, E., Grigoraki, V., Poziopoulos, C., Xilouri, I., Zorzou, M.P., Anagnostopoulos, N. Anagnostopoulos, A. (2004) Pulsed cyclophosphamide, thalidomide and dexamthosone: an oral regimen for previously treated patients with multiple myeloma. Hematology Journal, 5, 112 117.
11. Dimopoulos, M.A., Spencer, A., Attal, M., Prince, M., Harousseau, J.-L., Dmoszynska, A., Yu, Z., Olesnyckyj, M. Zeldis, J. (2005) Study of lanalidomide plus dextramethosone versus dextramethasone alone in relapsed or refractory multipl;e myeloma (MM): results of a Phase 3 study (MM-010). Blood, 106, 6a.
12. Durie, B.G. Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842 854.
13. Facon, T., Mary, J.Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J.L., Guillerm, G., Chaleteix, C., Dib, M., Voillat, L., Maisonneuve, H., Troncy, J., Dorvaux, V., Monconduit, M., Martin, C., Casassus, P., Jaubert, J., Jardel, H., Doyen, C., Kolb, B., Anglaret, B., Grosbois, B., Yakoub-Agha, I., Mathiot, C. Avet-Loiseau, H. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet, 370, 1209 1218.
14. Ferlay, J., Bray, F., Pisani, P. Parkin, D.M. (2004) GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No 5 Version 2.0. IARCPress, Lyon.
15. Friedberg, J., Cohen, P., Cheson, B.D., Robinson, K.S., Forero-Torres, A., Fayad, L., La Casce, A.S., Bessudo, A., Camacho, E.S., Williams, M.E., van der Jagt, R.H., Oliver, J. Benaim, E. (2005) Bendamustine HCl (TREANDATM) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-cell non-Hodgkin's lymphoma (NHL): results from a phase II multicenter single-agent study (SDX-105-01). Blood, 106 (Abstr 229).
16. Garcia-Sanz, R., Gonzalez-Porras, J.R., Hernandez, J.M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., Lopez, R., Grande-Garcia, C., Alegre, A., Vargas-Pabon, M., Gutierrez, O.N., Rodriguez, J.A. San Miguel, J.F. (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia, 18, 856 863.
17. Glasmacher, A., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H., von Lilienfeld-Toal, M., Orlopp, K., Schmidt-Wolf, I. Gorschluter, M. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 132, 584 593.
18. Guttner, J., Gutsche, W., Zchiesche, W., Wohlrabe, K., Jungstand, W., Ozegowski, W., Krebs, D. Roppnack, G. (1979) Beta-[1-Phenyl-5-bis(beta- chloroethyl)-amino-benzimidazolyl-(2)]-DL-alanin e (ZIMET 3164): an immunosuppressant without marked anti-cancer effect. Agents and Actions, 9, 521 526.
19. Haslett, P.A., Corral, L.G., Albert, M. Kaplan, G. (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Journal of Experimental Medicine, 187, 1885 1892.
20. Hatjiharissi, E., Terpos, E., Papaioannou, M., Hatjileontis, C., Kaloutsi, V., Galaktidou, G., Gerotziafas, G., Christakis, J. Zervas, K. (2004) The combination of intermediate doses of thalidomide and dexamethosone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematological Oncology, 22, 159 168.
21. Heider, A. Niederle, N. (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anti-Cancer Drugs, 12, 725 729.
22. Herold, M., Schulze, A., Niederwieser, D., Franke, A., Fricke, H.J., Richter, P., Freund, M., Ismer, B., Dachselt, K., Boewer, C., Schirmer, V., Weniger, J., Pasold, R., Winkelmann, C., Klinkenstein, C., Schulze, M., Arzberger, H., Bremer, K., Hahnfeld, S., Schwarzer, A., Muller, C. Muller, C. (2006) Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). Journal of Cancer Research and Clinical Oncology, 132, 105 112.
23. Hussein, M.A., Baz, R., Srkalovic, G., Agrawal, N., Suppiah, R., Hsi, E., Andresen, S., Karam, M.A., Reed, J., Faiman, B., Kelly, M. Walker, E. (2006) Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clinic Proceedings, 81, 889 895.
24. Knop, S., Straka, C., Haen, M., Schwedes, R., Hebart, H. Einsele, H. (2005) The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica, 90, 1287 1288.
25. Kropff, M.H., Lang, N., Bisping, G., Domine, N., Innig, G., Hentrich, M., Mitterer, M., Sudhoff, T., Fenk, R., Straka, C., Heinecke, A., Koch, O.M., Ostermann, H., Berdel, W.E. Kienast, J. (2003) Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British Journal of Haematology, 122, 607 616.
26. Kyriakou, C., Thomson, K., D'Sa, S., Flory, A., Hanslip, J., Goldstone, A.H. Yong, K.L. (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British Journal of Haematology, 129, 763 770.
27. Leoni, F., Casinin, C., Breschi, C., Alterini, R., Nozzoli, C. Bosi, A. (2006) Low dose botezomib, dexamethason, thalidomide plus liposomal doxorubicin in relapsed and refractory myeloma. Haematologica, 91 (Suppl. 1 281.
28. Mesters, R.M., Padro, T., Steins, M., Bieker, R., Retzlaff, S., Kessler, T., Kienast, J. Berdel, W.E. (2001) [Angiogenesis in patients with hematologic malignancies]. Onkologie, 24 (Suppl. 5 75 80.
29. Moehler, T.M., Neben, K., Benner, A., Egerer, G., Krasniqi, F., Ho, A.D. Goldschmidt, H. (2001) Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood, 98, 3846 3848.
30. Niemeyer, C., Bendall, H., Reifert, J., Bailey, B. Leoni, L.M. (2005) Mitotic Catastrophe Induced in Tumour Cells Treated with Bendamustine (TreandaTM, SDX 105), Proceedings of the American Association for Cancer Research, 46 Abstr 2291).
31. Ozegowski, W. Krebs, D. (1971) γ-(1-Methyl-5-bis-(β-chlor- äthyl)-amino-benzimidazolyl-(2))-buttersäurehydrochlorid, ein neues Zystostatikum aus der Reihe der Benzimidazol-Loste. Zentralblatt für Pharmakologie, 110, 1013 1019.
32. Padmanabhan, S., Miller, K., Musiel, L., Bernstein, Z., Czuczman, M., Yu, J. Chanan-Khan, A. (2006) Bortezomib (Velcade) incombination with liposomal doxorubicin (Doxil) and thalidomide (VDT) is ab active salvage regimen in patients (pts) with relapse (rel) or refractory (ref) multiple myeloma: final results of a Phase II study. Haematologica, 91 (Suppl. 1 277.
33. Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S., Rus, C., Triolo, S., Gallo, E., Pileri, A. Boccadoro, M. (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica, 86, 399 403.
34. Palumbo, A., Bertola, A., Falco, P., Rosato, R., Cavallo, F., Giaccone, L., Bringhen, S., Musto, P., Pregno, P., Caravita, T., Ciccone, G. Boccadoro, M. (2004) Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematology Journal, 5, 318 324.
35. Palumbo, A., Falco, P., Ambrosini, M.T., Petrucci, M.T., Musto, P., Caravita, T., Pregno, P., Bertola, A., Cavallo, F., Ciccone, G. Boccadoro, M. (2005) Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. European Journal of Haematology, 75, 391 395.
36. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P. Boccadoro, M. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367, 825 831.
37. Pönisch, W., Mitrou, P.S., Merkle, K., Herold, M., Assmann, M., Wilhelm, G., Dachselt, K., Richter, P., Schirmer, V., Schulze, A., Subert, R., Harksel, B., Grobe, N., Stelzer, E., Schulze, M., Bittrich, A., Freund, M., Pasold, R., Friedrich, T., Helbig, W. Niederwieser, D. (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Journal of Cancer Research and Clinical Oncology, 132, 205 212.
38. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431 436.
39. Richardson, P., Schlossman, R., Munshi, N., Avigan, D., Jagannath, S., Alsina, M., Doss, D., McKenney, M., Hande, K., Farrell, M., Gorelik, S., Colson, K., Warren, D., Lunde, L., Michelle, R., Cole, G., Mitsiades, C., Hideshima, T., Myers, T. Knight, R. (2005) A Phase I trial of lenalinomide (REVLIMID) with botezomib (VELCADE) in relapsed and refractory multiple myeloma. Blood, 106, 110a.
40. Richardson, P.G., Mitsiades, C., Schlossmann, R., Munshi, N. Anderson, K. (2007) New drugs for myeloma. The Oncologist, 12, 644 689.
41. Rummel, M.J., Al-Batran, S.E., Kim, S.Z., Welslau, M., Hecker, R., Kofahl-Krause, D., Josten, K.M., Dürk, H., Rost, A., Neise, M., von Grünhagen, U., Chow, K.U., Hansmann, M.L., Hoelzer, D. Mitrou, P.S. (2005) Bendamustine plus rituximab is effective and has a favourable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 3383 3389.
42. Sidra, G., Williams, C.D., Russell, N.H., Zaman, S., Myers, B. Byrne, J.L. (2006) Combination chemotherapy with cyclophosphamide, thalidomide and dexamethosone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica, 91, 862 863.
43. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565 1571.
44. Terpos, E., Mihou, D., Szydlo, R., Tsimirika, K., Karkantaris, C., Politou, M., Voskaridou, E., Rahemtulla, A., Dimopoulos, M.A. Zervas, K. (2005) The combination of intermediate doses of thalidomide with dexamethosone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodelling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia, 19, 1969 1976.
45. Von Hoff, D.D., Kuhn, J. Clark, G.M. (1988) Design and conduct of phase I trials. In : Cancer Clinical Trials - Methods and Practice (ed. by M.E. Buyse R.J. Sylvester pp. 210 220. Oxford University Press, Oxford.
46. Weber, D., Rankin, K., Gavino, M., Delasalle, K. Alexanian, R. (2003) Thalidomide alone0020or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology, 21, 16 19.
47. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E., Yu, Z., Yu, Z., Delap, R., Zeldis, J. Knight, R. (2006) Lanalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a Northe American phase III study (MM-009). Journal of Clinical Oncology, 24 (Suppl. 427s.
48. Weide, R., Hess, G., Köppler, H., Heymanns, J., Thomalla, J., Aldaoud, A., Losem, C., Schmitz, S., Haak, U., Huber, C., Unterhalt, M., Hiddemann, W. Dreyling, M. (2007) High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leukemia & Lymphoma, 48, 1299 1306.
49. Weidmann, E., Kim, S.Z., Rost, A., Schuppert, H., Seipelt, G., Hoelzer, D. Mitrou, P.S. (2002) Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Annals of Oncology, 13, 1285 1289.
50. Zangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A.V., Morris, C., Toor, A., Siegel, E., Fink, L. Tricot, G. (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood, 98, 1614 1615.
51. Zangari, M., Barlogie, B., Burns, M.J., Bolejack, V., Hollmig, K.A., van Rhee, F., Pineda-Roman, M., Elice, F. Tricot, G.J. (2005) Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): Long-term follow-up of Phase I-II trial UARK-37: Superior outcome in patients with normal cytogenetics and no prior T. Blood, 106, 717a.
52. Zervas, K., Dimopoulos, M.A., Hatzicharissi, E., Anagnostopoulos, A., Papaioannou, M., Mitsouli, C., Panagiotidis, P., Korantzis, J., Tzilianos, M. Maniatis, A. (2004) Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Annals of Oncology, 15, 134 138.